Government Information

Earl Gregg Swem Library

FTC v. Actavis Inc

Categories: Antitrust/Monopoly,Headlines,Health/Medical,Laws/Regulations,Supreme Court/courts

5-3 Supreme Court decision that so-called “pay for delay” deals, where drug companies pay to delay the introduction of generic competition may violate antitrust laws.  The Federal Trade Commission had argued that payments by Solvay Pharmaceuticals to delay generic competition for one of its products for 9 years were a violation of antitrust law.  From the Legal Information Institute of Cornell University